Biotech Funding Strategies for European Companies
Description
"Life has not become simpler and easier. It's become more complex. Success requires acknowledging this complexity early and building flexibility into every aspect of the business model.”
Renée Aguiar-Lucander is the CEO of Hansa Biopharma, appointed in April 2025. Renée brings rich expertise from seven years leading Calliditas Therapeutics through a dual NASDAQ listing and the first approved drug for IgA nephropathy, plus extensive healthcare investment experience at Omega Funds and 3i Group.
Speaking to PharmaSource at Nordic Life Science Days (NLSDays), Renée shares candid insights on the investment climate that's reshaped biotech over the past few years, the structural challenges facing European companies, and what early-stage biotechs need to focus on to survive an increasingly selective funding environment.
![[Exclusive] Society of Professional Pharmaceutical Consultants Launches - Interview with Ray Sison](https://s3.castbox.fm/7e/d8/06/985de3dbbde8a4d5fdaf5c7647ab089b8f_scaled_v1_400.jpg "[Exclusive] Society of Professional Pharmaceutical Consultants Launches - Interview with Ray Sison")
United States
